Zimbabwe has declined a significant American health deal valued at $367m (272 million pounds) over five years over Washington's demand for confidential information.
This rejection became public after a official document dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesman later explained that the United States was seeking genetic material for scientific study and profit but was unwilling to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further dialogue to secure a deal suitable to both sides so the country's vital HIV programme can be sustained.
Broader Background
This rejection comes after a comparable situation in Kenya, where a court halted a related health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
According to statements, Sixteen nations in Africa have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our population if a future disease outbreak arise."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its pursuit of bilateral health agreements were undermining frameworks already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage future global health emergencies.
"This mechanism is intended to ensure that when a country contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how subsequent co-operation might be structured in a way that honours the independence and dignity of each country."
Medical Community Response
A leading public health body stated it acknowledged the government's concerns, but urged that talks should continue since much of the country's Aids initiatives depended on international support.
"Where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
The halted deal underscores the complex tensions between accepting much-needed foreign assistance and protecting local interests in an ever more data-driven world.